GlassScriptPhysician profile
Ariela Holmer
NPI 1083032544
$156,209.66
in general payments reported to CMS, 2019-2025
18 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $49K · 2021: $74K · 2022: $2,243 · 2023: $28K · 2024: $1,087 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $3,639 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Travel and Lodging: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,255.00 |
| Food and Beverage | $3,638.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Travel and Lodging | $1,074.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85,065.47 | 2020-2025 | |
| Abbvie INC. | $42,318.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $20,192.01 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $4,705.40 | 2022-2023 | Rebyota |
| Celgene Corporation | $1,660.48 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $798.52 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $439.35 | 2021-2025 | Entyvio, Gattex |
| Boston Scientific Corporation | $235.57 | 2019 | |
| Lilly USA, LLC | $154.58 | 2023-2025 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $147.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $118.02 | 2022 | |
| Nestle Healthcare Nutrition INC. | $93.89 | 2021-2022 | |
| Organon LLC | $88.91 | 2022-2023 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $65.53 | 2025 | Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.77 | 2020-2024 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $39.57 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.94 | 2024 | Cyltezo |
| Sandoz INC. | $18.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariela Holmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.